Comparability of scalable, automated hMSC culture using manual and automated process steps

Biochemical Engineering Journal

Volumn 108, Issue , 2016, Pages 69-83

  Archibald, Peter R T ^a   Chandra, Amit ^a   Thomas, Dave ^b   Morley, Gary ^c   Lekishvili, Tamara ^c   Devonshire, Alison ^c   Williams, David J ^a  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b SARTORIUS STEDIM BIOTECH GMBH   (Germany)

^c LGC   (United Kingdom)

Author keywords

Bioprocess design; Centrifugation; Characterisation; Enzyme activity; Large scale cultivation; Scale up

Indexed keywords

CELL CULTURE; CELLS; CENTRIFUGATION; CYTOLOGY; ENZYME ACTIVITY; FLOW CYTOMETRY;

BIOPROCESS DESIGN; CELL BASED THERAPIES; CENTRIFUGATION PROCESS; CHARACTERISATION; FLOW CYTOMETRY ANALYSIS; LARGE SCALE CULTIVATIONS; MANUFACTURING PROCESS; SCALE-UP;

AUTOMATION;

CELL SURFACE MARKER; GLUCOSE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; PROSTAGLANDIN E2; VASCULOTROPIN;

ANALYTIC METHOD; ARTICLE; AUTOMATION; BIOPROCESS; CELL CULTURE; CELL GROWTH; CELL STRUCTURE; CELL THERAPY; CELL VIABILITY; CENTRIFUGATION; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; CULTURE VESSEL; FLOW CYTOMETRY; GENERAL MEDICAL DEVICE; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SCALE UP; SHORT TANDEM REPEAT;

EID: 84959320722     PISSN: 1369703X     EISSN: 1873295X     Source Type: Journal    
DOI: 10.1016/j.bej.2015.07.001     Document Type: Article

References (68)

1. Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970, 3:393-403.
2. Caplan A.I. Mesenchymal stem cells. J. Orthopaedic Res. 1991, 9:641-650.
3. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
4. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J. Cell Biochem. 2006, 98:1076-1084.
5. Krampera M., Galipeau J., Shi Y., Tarte K., Sensebe L. (ISCT) MCotISfCT. Immunological characterization of multipotent mesenchymal stromal cells - the International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013, 15:1054-1061.
6. Thomson H. Bioprocessing of embryonic stem cells for drug discovery. Trends Biotechnol. 2007, 25:224-230.
7. Hussain W., Moens N., Veraitch F.S., Hernandez D., Mason C., Lye G.J. Reproducible culture and differentiation of mouse embryonic stem cells using an automated microwell platform. Biochem. Eng. J. 2013, 77:246-257.
8. Terstegge S., Laufenberg I., Pochert J., et al. Automated maintenance of embryonic stem cell cultures. Biotechnol. Bioeng. 2007, 96:195-201.
9. Thomas R.J., Chandra A., Liu Y., Hourd P.C., Conway P.P., Williams D.J. Manufacture of a human mesenchymal stem cell population using an automated cell culture platform. Cytotechnology 2007, 55:31-39.
10. Thomas R.J., Anderson D., Chandra A., et al. Automated, scalable culture of human embryonic stem cells in feeder-free conditions. Biotechnol. Bioeng. 2009, 102:1636-1644.
11. Zenger V., Vogt R., Mandy F., Schwartz A., Marti G. Quantitative flow cytometry: inter-laboratory variation. Cytometry 1998, 33(2):138-145.
12. Krampera M. Mesenchymal stromal cell 'licensing': a multistep process. Leukemia 2011, 25:1408-1414.
13. Galipeau J. The mesenchymal stromal cells dilemma - does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 2013, 15:2-8.
14. Yagi H., Soto-Gutierrez A., Parekkadan B., et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplantation 2010, 19:667-679.
15. Tolar J., Le Blanc K., Keating A., Blazar B.R. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 2010, 28:1446-1455.
16. Menard C., Pacelli L., Bassi G., et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality control. Stem Cells Dev. 2013, 22:1789-1801.
17. La Meirelles S., Fontes A.M., Covas D.T., Caplan A.I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009, 20:419-427.
18. Prockop D.J., Oh J.Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol. Ther. 2012, 20:14-20.
19. Prockop D.J. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells 2013, 31:2042-2046.
20. Liu K., Chi L., Guo L., et al. The interactions between brain microvascular endothelial cells and mesenchymal stem cells under hypoxic conditions. Microvasc. Res. 2008, 75:59-67.
21. Rehman J., Traktuev D., Li J., et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004, 109:1292-1298.
22. Hu X., Yu S.P., Fraser J.L., et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J. Thorac. Cardiovasc. Surg. 2008, 135:799-808.
23. Li W., Ma N., Ong L.L., et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 2007, 25:2118-2127.
24. Tögel F., Weiss K., Yang Y., Hu Z., Zhang P., Westenfelder C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am. J. Physiol. Renal Physiol. 2007, 292:F1626-F1635.
25. Chacko S.M., Ahmed S., Selvendiran K., Kuppusamy M.L., Khan M., Kuppusamy P. Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. Am. J. Physiol. Cell Physiol. 2010, 299:C1562-C1570.
26. Al-Khaldi A., Al-Sabti H., Galipeau J., Lachapelle K. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann. Thorac. Surg. 2003, 75:204-209.
27. Chan A.K., Heathman T.R., Coopman K., Hewitt C.J. Multiparameter flow cytometry for the characterisation of extracellular markers on human mesenchymal stem cells. Biotechnol. Lett. 2014, 36:731-741.
28. Wei L., Fraser J.L., Lu Z.Y., Hu X., Yu S.P. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol. Dis. 2012, 46:635-645.
29. Potier E., Ferreira E., Andriamanalijaona R., et al. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 2007, 40:1078-1087.
30. Meisel R., Zibert A., Laryea M., Göbel U., Däubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
31. Feng G.S., Taylor M.W. Interferon gamma-resistant mutants are defective in the induction of indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:7144-7148.
32. Takikawa O., Kuroiwa T., Yamazaki F., Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 1988, 263:2041-2048.
33. Matin A., Streete I.M., Jamie I.M., Truscott R.J., Jamie J.F. A fluorescence-based assay for indoleamine 2,3-dioxygenase. Anal. Biochem. 2006, 349:96-102.
34. Russell K.C., Tucker H.A., Bunnell B.A., et al. Cell-surface expression of neuron-glial antigen 2 (NG2) and melanoma cell adhesion molecule (CD146) in heterogeneous cultures of marrow-derived mesenchymal stem cells. Tissue Eng. Part A 2013, 19:2253-2266.
35. Zimmerlin L., Donnenberg V.S., Pfeifer M.E., et al. Stromal vascular progenitors in adult human adipose tissue. Cytometry A 2010, 77:22-30.
36. Lin C.S., Ning H., Lin G., Lue T.F. Is CD34 truly a negative marker for mesenchymal stromal cells. Cytotherapy 2012, 14:1159-1163.
37. Nery A.A., Nascimento I.C., Glaser T., Bassaneze V., Krieger J.E., Ulrich H. Human mesenchymal stem cells: from immunophenotyping by flow cytometry to clinical applications. Cytometry A 2013, 83:48-61.
38. Butler J.M. Genetics and genomics of core short tandem repeat loci used in human identity testing. J. Forensic Sci. 2006, 51:253-265.
39. Masters J.R., Thomson J.A., Daly-Burns B., et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8012-8017.
40. Clayton T.M., Whitaker J.P., Sparkes R., Gill P. Analysis and interpretation of mixed forensic stains using DNA STR profiling. Forensic Sci. Int. 1998, 91:55-70.
41. Liu Y., Hourd P., Chandra A., Williams D.J. Human cell culture process capability: a comparison of manual and automated production. J. Tissue Eng. Regener. Med. 2010, 4:45-54.
42. Westoby M., Rogers J.K., Haverstock R., Romero J., Pieracci J. Modeling industrial centrifugation of mammalian cell culture using a capillary based scale-down system. Biotechnol. Bioeng. 2011, 108:989-998.
43. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010, 5:e10088.
44. François M., Romieu-Mourez R., Li M., Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 2012, 20:187-195.
45. Krampera M., Cosmi L., Angeli R., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24:386-398.
46. Tattevin P., Monnier D., Tribut O., et al. Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J. Infect. Dis. 2010, 201:956-966.
47. Mindaye S.T., Ra M., Lo Surdo J., Bauer S.R., Alterman M.A. Improved proteomic profiling of the cell surface of culture-expanded human bone marrow multipotent stromal cells. J. Proteomics 2013, 78:1-14.
48. Siegel G., Kluba T., Hermanutz-Klein U., Bieback K., Northoff H., Schäfer R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013, 11:146.
49. Izadpanah R., Kaushal D., Kriedt C., et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res. 2008, 68:4229-4238.
50. Lee M.W., Kim D.S., Yoo K.H., et al. Human bone marrow-derived mesenchymal stem cell gene expression patterns vary with culture conditions. Blood Res. 2013, 48:107-114.
51. Németh K., Leelahavanichkul A., Yuen P.S., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009, 15:42-49.
52. Yañez R., Oviedo A., Aldea M., Bueren J.A., Lamana M.L. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp. Cell Res. 2010, 316:3109-3123.
53. Najar M., Raicevic G., Boufker H.I., et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's jelly and bone marrow sources. Cell. Immunol. 2010, 264:171-179.
54. Prasanna S.J., Gopalakrishnan D., Shankar S.R., Vasandan A.B. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010, 5:e9016.
55. Solchaga L.A., Zale E.A. Prostaglandin E2: a putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells. Am. J. Stem Cells 2012, 1:138-145.
56. Bouffi C., Bony C., Courties G., Jorgensen C., Noël D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010, 5:e14247.
57. Zafranskaya M., Nizheharodava D., Yurkevich M., et al. PGE2 contributes to in vitro MSC-mediated inhibition of non-specific and antigen-specific T cell proliferation in MS patients. Scand. J. Immunol. 2013, 78:455-462.
58. Phinney D.G., Prockop D.J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem Cells 2007, 25:2896-2902.
59. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012, 10:709-716.
60. Rastegar F., Shenaq D., Huang J., et al. Mesenchymal stem cells: molecular characteristics and clinical applications. World J. Stem Cells 2010, 2:67-80.
61. Caplan A.I. All MSCs are pericytes. Cell Stem Cell 2008, 3:229-230.
62. Caplan A.I., Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011, 9:11-15.
63. Fernández Vallone V.B., Romaniuk M.A., Choi H., Labovsky V., Otaegui J., Chasseing N.A. Mesenchymal stem cells and their use in therapy: what has been achieved. Differentiation 2013, 85:1-10.
64. Pourrajab F., Forouzannia S.K., Tabatabaee S.A. Molecular characteristics of bone marrow mesenchymal stem cells, source of regenerative medicine. Int. J. Cardiol. 2013, 163:125-131.
65. Linero I., Chaparro O. Paracrine effect of mesenchymal stem cells derived from human adipose tissue in bone regeneration. PLoS One 2014, 9:e107001.
66. Kagiwada H., Yashiki T., Ohshima A., Tadokoro M., Nagaya N., Ohgushi H. Human mesenchymal stem cells as a stable source of VEGF-producing cells. J. Tissue Eng. Regener. Med. 2008, 2:184-189.
67. Potapova I.A., Gaudette G.R., Brink P.R., et al. Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem cells 2007, 25:1761-1768.
68. Bloom D.D., Centanni J.M., Bhatia N., et al. A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. Cytotherapy 2015, 17:140-151.